CIENCIASMEDICASNEWS: noviembre 2025

https://www.medscape.org/viewarticle/expert-discussion-key-new-data-cll-and-mcl-how-may-it-impact-2025a1000pm5?page=1&sso=true&uac=148436CN&src=mkmcmr_reeng_recap_mscpedu_activity An Expert Discussion of Key New Data in CLL and MCL: How May It Impact Future Practice? Below are some key learning points to help reinforce the impact of this activity. ☑ CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) TRIALS: • GAIA/CLL13: The triplet ibrutinib-venetoclax-obinutuzumab showed superior progression-free survival (PFS) vs doublets and chemoimmunotherapy, but increased toxicity limits its use in all patient populations. • CAPTIVATE: Fixed-duration ibrutinib + venetoclax (15 months, median PFS not reached) achieved 66% PFS at 5.5 years, with successful retreatment possible. Ibrutinib + venetoclax achieved undetectable minimal residual disease (uMRD) in 60% of patients at end of therapy (EOT), which is a strong predictor for long-term PFS. • FLAIR: MRD-guided ibrutinib plus venetoclax outperformed continuous ibrutinib and fludarabine-cyclophosphamide-rituximab (FCR), with 73% of patients able to stop treatment by 60 months based on undetectable MRD achievement. • BRUIN CLL-321: Pirtobrutinib showed superior PFS (14 months) vs physician's choice of idelalisib + rituximab or bendamustine + rituximab in covalent Bruton tyrosine kinase (cBTK) inhibitor-exposed patients. In patient-reported outcomes, pirtobrutinib also demonstrated a clinically meaningful improvement at all visits in CLL/small lymphocytic lymphoma (SLL)-related symptoms, physical function, and fatigue. • CaDAnCe-101: The BTK degrader BGB-16673 was safe and well tolerated and achieved a 93.8% response rate in heavily pretreated patients (94% prior cBTK inhibitor exposed), representing a promising new drug class for relapsed/refractory (R/R) CLL/SLL. • Sonrotoclax + zanubrutinib: This next-generation B-cell lymphoma-2 (BCL-2)-BTK combination achieved 100% overall response rates and 48% complete response (CR)/CR with incomplete hematologic recovery (CRi) rates at 320 mg and a 30-month PFS of 95% in R/R CLL/SLL. ☑ MANTLE CELL LYMPHOMA (MCL) TRIALS: • ECHO: Adding acalabrutinib to bendamustine-rituximab significantly improved PFS in high-risk patients with MCL, particularly those with TP53 mutations, high Ki-67, and blastoid histology. • SYMPATICO: First-line ibrutinib + venetoclax for 2 years followed by ibrutinib maintenance showed durable responses in older patients and those with and without TP53 mutations, with PFS approaching 2 years in patients with TP53 mutation. • Mosunetuzumab + polatuzumab: This CD20 bispecific plus antibody-drug conjugate (ADC) combination achieved ~90% response rates, with ~80% CR in BTK inhibitor-exposed patients with MCL, with manageable grade 1 to 2 cytokine release syndrome (CRS). • VALOR: The chemo-free triplet rituximab + venetoclax + lenalidomide showed a 70% 5-year PFS in frontline MCL; this included high-risk disease, but patients with TP53 mutation had poor outcomes. • GoldiLox: Glofitamab + pirtobrutinib achieved ~80% response rates in BTK inhibitor-exposed patients with MCL, with enhanced steroid prophylaxis improving tolerability. • Sonrotoclax + zanubrutinib MCL: This combination achieved ~80% response rates, with a 70% CR rate and 84% 24-month duration of response in patients with R/R MCL.

WHO releases first-ever global guideline for prevention, diagnosis and treatment of infertility

https://www.news-medical.net/news/20251129/WHO-releases-first-ever-global-guideline-for-prevention-diagnosis-and-treatment-of-infertility.aspx The World Health Organization (WHO) today called on countries to make fertility care safer, fairer and more affordable for all in its first-ever global guideline for the prevention, diagnosis and treatment of infertility.

Mediterranean diet benefits identified by SPARC levels

https://www.news-medical.net/news/20251129/Mediterranean-diet-benefits-identified-by-SPARC-levels.aspx A new study published in Life Metabolism reports that a single post-meal blood biomarker, 1-hour postprandial SPARC (SPARC-1H), can predict who will benefit most from adopting a Mediterranean diet. The discovery provides one of the clearest examples to date of how precision nutrition can identify individualized dietary responses using a simple blood test rather than complex multi-omics models.

Measles deaths plummet but infections surge worldwide

https://www.news-medical.net/news/20251129/Measles-deaths-plummet-but-infections-surge-worldwide.aspx Global immunization efforts have led to an 88% drop in measles deaths between 2000 and 2024, according to a new report from the World Health Organization (WHO). Nearly 59 million lives have been saved by the measles vaccine since 2000.

Fanconi anemia patients show striking metabolic differences

https://www.news-medical.net/news/20251129/Fanconi-anemia-patients-show-striking-metabolic-differences.aspx

Alternate-day fasting cuts body fat but also reduces muscle

New research shows that while four weeks of alternate-day fasting can quickly reduce body weight and fat, it also leads to a measurable loss of muscle, and adding a whey protein shake during fasting days isn’t enough to stop it. https://www.news-medical.net/news/20251128/Alternate-day-fasting-cuts-body-fat-but-also-reduces-muscle.aspx

perspectives in breast cancer care SEPTEMBER 18—19, 2026 WASHINGTON, D.C. Fairmont Washington D.C. Georgetown

https://www.breastcancercareconference.com/?utm_campaign=medscape.org+banner&utm_source=mrk&utm_medium=ban&utm_content=dban

Patients Progressing on an AI ± CDK4/6 Inhibitors: From Biomarkers to Treatment Strategies Authors: Manali Bhave, MD; Nadia Harbeck, MD, PhD

https://www.medscape.org/viewarticle/patients-progressing-ai-cdk4-6-inhibitors-biomarkers-2025a1000wtp?page=1

Optimizing Outcomes for Thyroid Cancer With NTRK Gene Fusions: Precision Care, Patient Impact Authors: Jaume Capdevila, MD, PhD; Gary Bloom; Umberto Malapelle, PhD; Lori J. Wirth, MD

https://www.medscape.org/viewarticle/1002660?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251128-OUS-HONC-1002660-cta

Managing Patients With HR+/HER2- EBC: Assess Your Knowledge Authors: Reshma Mahtani, DO

https://www.medscape.org/viewarticle/managing-patients-hr-her2-ebc-assess-your-knowledge-2025a1000ier?page=1&sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251129-OUS-HONC-managing-patients-hr-her2-ebc-assess-your-knowledge-2025a1000ier-cta

viernes, 28 de noviembre de 2025

Common sleep problem tied to serious neurological disorder in major new study By Khloe Quill Fox News Published November 26, 2025 2:16pm EST

Common sleep problem tied to serious neurological disorder in major new study CPAP therapy could reduce Parkinson's risk by 30% when started early, research suggests By Khloe Quill Fox News Published November 26, 2025 2:16pm EST https://www.foxnews.com/health/common-sleep-problem-tied-serious-neurological-disorder-major-new-study

Stop heartburn before it starts: 5 dinner mistakes to avoid, from a GI doctor By Khloe Quill Fox News Published November 27, 2025 7:00am EST

Stop heartburn before it starts: 5 dinner mistakes to avoid, from a GI doctor Gastrointestinal doctor reveals why digestion-related symptoms flare during the holidays By Khloe Quill Fox News Published November 27, 2025 7:00am EST https://www.foxnews.com/health/stop-heartburn-before-starts-5-dinner-mistakes-avoid-from-gi-doctor

Alzheimer's risk declines sharply with one daily lifestyle change, researchers say By Amy McGorry Fox News Published November 28, 2025 7:00am EST

Alzheimer's risk declines sharply with one daily lifestyle change, researchers say Higher activity levels in midlife and late life linked to lower dementia rates By Amy McGorry Fox News Published November 28, 2025 7:00am EST https://www.foxnews.com/health/alzheimers-risk-declines-sharply-one-daily-lifestyle-change-researchers-say

Fox News Health Newsletter: Common sleep problem tied to serious brain disorder By Fox News Staff Fox News Published November 28, 2025 2:33pm EST

Fox News Health Newsletter: Common sleep problem tied to serious brain disorder And more of the top Fox News Health stories and videos from the past week By Fox News Staff Fox News Published November 28, 2025 2:33pm EST https://www.foxnews.com/health/fox-news-health-newsletter-common-sleep-problem-tied-serious-brain-disorder

Type 1 diabetes reversed in landmark study, paving the way for human studies By Angelica Stabile Fox News Published November 28, 2025 1:38pm EST

Type 1 diabetes reversed in landmark study, paving the way for human studies Cell transplants reversed disease in 100% of mice in lab study Angelica Stabile By Angelica Stabile Fox News Published November 28, 2025 1:38pm EST https://www.foxnews.com/health/type-1-diabetes-reversed-landmark-study-paving-way-human-studies

The deadly cancer hiding in plain sight — and why most patients never get screened By Khloe Quill Fox News Published November 25, 2025 11:56am EST

The deadly cancer hiding in plain sight — and why most patients never get screened Only about 35% of those diagnosed with lung cancer met the current screening criteria, researchers say By Khloe Quill Fox News Published November 25, 2025 11:56am EST https://www.foxnews.com/health/deadly-cancer-hiding-plain-sight-why-most-patients-never-get-screened?lid=r2nltjcuqq6h

Persistent Painful Rash in a 63-Year-Old Man With Joint Swelling +++

Persistent Painful Rash in a 63-Year-Old Man With Joint Swelling Persistent Painful Rash in a 63-Year-Old Man With Joint Swelling Celter Odango, MS; Nicole L. Edmonds, MD; Richard H. Flowers, MD https://reference.medscape.com/viewarticle/persistent-painful-rash-63-year-old-man-joint-swelling-2025a1000v9j?ecd=wnl_edit_tpal_etid7909880&uac=148436CN&impID=7909880 November 26, 2025 Time to Retire the Term ‘Metabolically Healthy Obesity’? Time to Retire the Term ‘Metabolically Healthy Obesity’? Marilynn Larkin https://www.medscape.com/viewarticle/time-retire-term-metabolically-healthy-obesity-2025a1000x54?ecd=wnl_edit_tpal_etid7909880&uac=148436CN&impID=7909880 November 26, 2025 2025 Highlights From the Movement Disorders Society Annual Meeting 2025 Highlights From the Movement Disorders Society Annual Meeting Indu Subramanian, MD; Alfonso Fasano, MD, PhD, FAAN https://www.medscape.com/viewarticle/2025-highlights-movement-disorders-society-annual-meeting-2025a1000wsa?ecd=wnl_edit_tpal_etid7909880&uac=148436CN&impID=7909880 November 26, 2025

Antibody-Drug Conjugates in Practice: Contemporary Questions for the Treatment of Metastatic Breast Cancer Authors: Judy King, MRCP, PhD; Giuseppe Curigliano, MD, PhD; Peter Schmid, MD, PhD, FRCP

https://www.medscape.org/viewarticle/1002851?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251127-OUS-HONC-1002851-cta

Highlights From the Annual Oncology Meeting: Clinical Integration of Therapeutic Innovations in Glioma Authors: Matthias Preusser, MD; Manmeet S. Ahluwalia, MD, MBA, FASCO; L. Nicolas Gonzalez Castro, MD, PhD; Jeremy Pivo

https://www.medscape.org/viewarticle/1002677?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251128-OUS-HONC-1002677-cta

The Lancet Conference Alerts | Read our late-breaking content from BTS Winter Meeting 2025 +++...

Oral corticosteroid reduction and discontinuation in adults with corticosteroid-dependent, severe, uncontrolled asthma treated with tezepelumab (WAYFINDER): a multicentre, single-arm, phase 3b trial Open Access https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(25)00359-5/fulltext?dgcid=hubspot_email_conferencealerts_bts25&utm_campaign=conferencealerts&utm_medium=email&_hsenc=p2ANqtz-9xgpp1L9ANpjtX4zNDGMGdHCP0E_P557ZcGWVvRN0zGajf0K1q9H0Rf2_XLr6ge1QnmX0VkHKlaMoof-oPtXATeRW1Rg&_hsmi=391783220&utm_content=391783220&utm_source=hs_email COMMENTS Efficacy of tezepelumab in reducing oral corticosteroid use in severe asthma Free with registration until Dec 6, 2025 https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(25)00395-9/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_bts25&_hsenc=p2ANqtz-9N7YZ8Lglfwh-drZfqh25_nsTIpx7dq0iVjZTmiWUXxM04EMO2FucYIhvycuDm46NYNEVEB21_vD_LbgIdL-la-xzAaA&_hsmi=391783220&utm_content=391783220&utm_source=hs_email November 27, 2025 Comment Time to pull the plug on subglottic secretion drainage? Michael Klompas,Richard Branson https://www.thelancet.com/journals/lanres/onlinefirst

Most Read Cancer Science & Oncogenesis

https://read.qxmd.com/collection/1133?ecd=wnl_readmost_251128

Editorial p2509 The Global Fund and the future of global health The Lancet + +... +

Efficacy of once-daily, high-dose, oral insulin immunotherapy in children genetically at risk for type 1 diabetes (POInT): a European, randomised, placebo-controlled, primary prevention trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01726-X/fulltext?dgcid=raven_jbs_etoc_feature_lancet Nov 29, 2025 Volume 406Number 10519p2509-2600 https://www.thelancet.com/journals/lancet/issue/vol406no10519/PIIS0140-6736(25)X0048-9 Editorial p2509 The Global Fund and the future of global health The Lancet https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02421-3/fulltext?dgcid=raven_jbs_etoc_email

HER2 Evolution in Gastroesophageal Cancer: New Therapies and Optimized Outcomes Authors: Samuel J. Klempner, MD, FASCO

https://www.medscape.org/viewarticle/her2-evolution-gastroesophageal-cancer-new-therapies-and-2025a1000x2t?page=1&sso=true&impID=7911424&uac=148436CN&src=wnl_tpal_251128_mscpedu

Anticoagulation Guideline Recommendations for Stroke Prevention From Around the World: Who Has It Right? Authors: Felicita Andreotti, MD, PhD; Masaharu Akao, MD, PhD; Alan Bell, MD; Yutao Guo, PhD

https://www.medscape.org/viewarticle/1002980_sidebar10?sso=true&uac=148436CN&src=mkmcmr_driv_il_mscpedu_251128-1002980-ES_LANG-NEUR

Emily Says Ketamine Changed Her Life! – In-Depth Doctor’s Interview By Ivanhoe Broadcast News on July 15, 2024

https://www.ivanhoe.com/interview/emily-says-ketamine-changed-her-life-in-depth-doctors-interview/

A GAME CHANGER FOR ADVANCED KIDNEY CANCER

A Game Changer for Advanced Kidney Cancer By Ivanhoe Broadcast News on December 5, 2025 https://www.ivanhoe.com/?p=36369&preview=1&_ppp=24fb732946

RARE BUT RISING: APPENDIX CANCER RATES TRIPLE

Rare But Rising: Appendix Cancer Rates Triple By Ivanhoe Broadcast News on December 3, 2025 https://www.ivanhoe.com/?p=36362&preview=1&_ppp=baa31e5765

WHAT CAUSES WEIGHT GAIN?

What Causes Weight Gain? By Ivanhoe Broadcast News on December 2, 2025 https://www.ivanhoe.com/?p=36360&preview=1&_ppp=5e0b9da870

BRAIN SURGERY BEFORE HIGH SCHOOL

Brain Surgery Before High School By Ivanhoe Broadcast News on December 1, 2025 https://www.ivanhoe.com/?p=36357&preview=1&_ppp=355908d6f2

CRAZY ABOUT CREATINE?

Crazy About Creatine? By Ivanhoe Broadcast News on December 4, 2025 https://www.ivanhoe.com/?p=36366&preview=1&_ppp=53ac2e99b4

jueves, 27 de noviembre de 2025

Late HIV diagnoses threaten Europe’s progress toward ending AIDS by 2030

https://www.news-medical.net/news/20251127/Late-HIV-diagnoses-threaten-Europee28099s-progress-toward-ending-AIDS-by-2030.aspx

Social support plays an important role in health and well-being of older adults

https://www.news-medical.net/news/20251127/Social-support-plays-an-important-role-in-health-and-well-being-of-older-adults.aspx

SNAP and Medicaid cuts could strip students of school meals

https://www.news-medical.net/news/20251127/SNAP-and-Medicaid-cuts-could-strip-students-of-school-meals.aspx A federal bill is reshaping who qualifies for free school meals, putting high-need students at risk and forcing schools to absorb new administrative and financial burdens as they fight to keep kids fed.

Man With Lung Cancer Shows Pseudoprogression, No Tumour Wolfgang Paik Medscape UK November 26, 2025

https://www.medscape.com/viewarticle/man-lung-cancer-shows-pseudoprogression-no-tumour-2025a1000x1l

Risk for Melanoma in Suspected Pyogenic Granuloma Warrants Histopathologic Examination Edited by Vineeta Teotia Medscape UK November 27, 2025

https://www.medscape.com/viewarticle/risk-melanoma-suspected-pyogenic-granuloma-warrants-2025a1000wy4

MHRA Approves Inavolisib for PIK3CA-Mutated Breast Cancer Zeel Mehta Medscape UK November 27, 2025

https://www.medscape.com/viewarticle/mhra-approves-inavolisib-pik3ca-mutated-breast-cancer-2025a1000x72

Could Carba1 Prevent Chemotherapy-Induced Neuropathy? Anne Gaëlle Moulun Medscape UK November 27, 2025

https://www.medscape.com/viewarticle/could-carba1-prevent-chemotherapy-induced-neuropathy-2025a1000x60

Expanded Lung Cancer Screening Could Avert Many More Deaths Ernie Mundell November 25, 2025

https://www.medscape.com/viewarticle/expanded-lung-cancer-screening-could-avert-many-more-deaths-2025a1000wxo

Maximizing Patient Engagement: Assessing Pain and Defining Treatment Goals for Victims of Partner Violence Authors: Debra Houry, MD, MPH

https://www.medscape.org/viewarticle/1003119

HER2 Evolution in Gastroesophageal Cancer: New Therapies and Optimized Outcomes Authors: Samuel J. Klempner, MD, FASCO

https://www.medscape.org/viewarticle/her2-evolution-gastroesophageal-cancer-new-therapies-and-2025a1000x2t?page=1

Expanding the Frontiers of HER2-Targeted Therapy in Gynecologic Cancers Authors: Ana Oaknin, MD, PhD; Susana Banerjee, MBBS, MA, FRCP, PhD; Ramez Eskander, MD; Diana N. Ionescu, MD

https://www.medscape.org/viewarticle/expanding-frontiers-her2-targeted-therapy-gynecologic-2025a1000udv?page=1&sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251126-OUS-HONC-expanding-frontiers-her2-targeted-therapy-gynecologic-2025a1000udv-cta

ADHD diagnoses are growing. What’s going on?

ADHD diagnoses are growing. What’s going on? More children and adults are being diagnosed with ADHD in some countries. Science is helping to understand why — and how best to provide support. By Helen Pearson https://www.nature.com/articles/d41586-025-03855-2?utm_source=Live+Audience&utm_campaign=8011944384-nature-briefing-daily-20251126&utm_medium=email&utm_term=0_-33f35e09ea-50432164

We are all mosaics: vast genetic diversity found between cells in a single person By Heidi Ledford

https://www.nature.com/articles/d41586-025-03768-0?utm_source=Live+Audience&utm_campaign=8011944384-nature-briefing-daily-20251126&utm_medium=email&utm_term=0_-33f35e09ea-50432164

‘They don’t have symptoms’: CAR-T therapies send autoimmune diseases into remission

‘They don’t have symptoms’: CAR-T therapies send autoimmune diseases into remission Engineered T cells that have been used to treat ulcerative colitis, rheumatoid arthritis and lupus show promising results. By Rachel Fieldhouse https://www.nature.com/articles/d41586-025-03885-w?utm_source=Live+Audience&utm_campaign=8011944384-nature-briefing-daily-20251126&utm_medium=email&utm_term=0_-33f35e09ea-50432164

Modern Gastrointestinal Cancer Therapies

https://www.medscape.org/advances/modern-gastrointestinal-cancer-therapies-2025a1000cys?sso=true&uac=148436CN&src=mkmcmr_driv_32025_mscpedu_416293.01_ace_launch

Navigating Biomarker Conversations: Empowering Patient Understanding in Gastroesophageal Cancer Authors: Sylvie Lorenzen, MD, PhD

https://www.medscape.org/viewarticle/1002840?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251126-OUS-HONC-1002840-cta

Highlights from the Annual Neurosurgical Conference: New Standards in Diffuse Lower-Grade Glioma Authors: Mitchel S. Berger, MD; Macarena de la Fuente, MD; Michael Lim, MD

https://www.medscape.org/viewarticle/1002598?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251126-OUS-HONC-1002598-cta

The clock is ticking for UNAIDS The Lancet HIV ++ +...

The clock is ticking for UNAIDS The Lancet HIV https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(25)00331-5/fulltext?dgcid=raven_jbs_etoc_email Efficacy and safety of a mosaic HIV-1 vaccine regimen in men who have sex with men and transgender individuals (HVTN 706/HPX3002/Mosaico): a global, randomised, double-blind, placebo-controlled, phase 3 trial https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(25)00195-X/abstract?dgcid=raven_jbs_etoc_feature_lanhiv Dec 2025 Volume 12Number 12e811-e898 https://www.thelancet.com/journals/lanhiv/issue/vol12no12/PIIS2352-3018(25)X0012-6

What is the recommended dosing regimen for vitamin D and calcium in patients with osteoporosis? (MEDSCAPE AI) +... +++ +++

https://www.medscape.com/ai-search?ecd=mkm_ret_251127_mscpmrk-OUS_DisReferences_etid7904630&uac=148436CN&impID=7904630 Read By QxMD What is The Newest Evidence About PCSK9 Inhibitors? https://read.qxmd.com/read/41210917/obesity-and-chronic-kidney-disease-the-dual-epidemic-in-cardiovascular-health?ecd=mkm_ret_251127_mscpmrk-OUS_DisReferences_etid7904630&uac=148436CN&impID=7904630&sso=true&redirected=slug Obesity and Chronic Kidney Disease: The Dual Epidemic in Cardiovascular Health. Christopher Henry Grant, Samira Bell European Cardiology 2025 Diuretic Use in Heart Failure Diuretic Use in Heart Failure. George Nassar, Robert Jameson Reviews in Cardiovascular Medicine 2025 October https://read.qxmd.com/read/41209127/diuretic-use-in-heart-failure?ecd=mkm_ret_251127_mscpmrk-OUS_DisReferences_etid7904630&uac=148436CN&impID=7904630&sso=true&redirected=slug PCOS in 2025: Insights & Innovations PCOS in 2025 - Insights and Innovations. Anuja Dokras Fertility and Sterility 2025 September 22 https://read.qxmd.com/read/40992713/pcos-in-2025-insights-and-innovations?ecd=mkm_ret_251127_mscpmrk-OUS_DisReferences_etid7904630&uac=148436CN&impID=7904630&sso=true&redirected=slug Diseases & Conditions Sweet Syndrome https://emedicine.medscape.com/article/1122152-overview?ecd=mkm_ret_251127_mscpmrk-OUS_DisReferences_etid7904630&uac=148436CN&impID=7904630 Rh Incompatibility https://emedicine.medscape.com/article/797150-overview?ecd=mkm_ret_251127_mscpmrk-OUS_DisReferences_etid7904630&uac=148436CN&impID=7904630 Silicosis https://emedicine.medscape.com/article/302027-overview?ecd=mkm_ret_251127_mscpmrk-OUS_DisReferences_etid7904630&uac=148436CN&impID=7904630

Frontline Frontiers: Revolutionizing Extensive-Stage SCLC Care Through Treatment Innovation Authors: Solange Peters, MD, PhD; Martin Reck, MD; Melissa Johnson, MD Faculty

https://www.medscape.org/viewarticle/1002626?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251127-OUS-HONC-1002626-cta

miércoles, 26 de noviembre de 2025

How Breast Cancer Changed This Surgeon’s Perspective Siobhan Harris Medscape UK November 26, 2025

How Breast Cancer Changed This Surgeon’s Perspective Siobhan Harris Medscape UK November 26, 2025 https://www.medscape.com/viewarticle/how-breast-cancer-changed-this-surgeons-perspective-2025a1000x3t

Cardiotoxicity Risk Lingers for Cancer Survivors Maurie Markman, MD November 26, 2025

https://www.medscape.com/viewarticle/cardiotoxicity-risk-lingers-cancer-survivors-2025a1000uy4

ASTRO Issues First Guideline on Gastric Cancer Radiotherapy Megan Brooks November 26, 2025

https://www.medscape.com/viewarticle/astro-issues-first-guideline-gastric-cancer-radiotherapy-2025a1000x2k

Could a new H3N2 flu variant spark a severe 2025–2026 US season (Medscape AI)

Could a new H3N2 flu variant spark a severe 2025–2026 US season https://www.medscape.com/ai-search?query=Could%20a%20new%20H3N2%20flu%20variant%20spark%20a%20severe%202025%E2%80%932026%20US%20season&ecd=mkm_ret_251126_mscpmrk_idhiv_top-content_etid7902302&uac=148436CN&impID=7902302

AI model outperforms breast density assessment in breast cancer risk stratification

https://www.news-medical.net/news/20251126/AI-model-outperforms-breast-density-assessment-in-breast-cancer-risk-stratification.aspx

What Makes a Smart Drug? Inside the Science of Multi-Target Therapeutics

https://www.news-medical.net/health/What-Makes-a-Smart-Drug-Inside-the-Science-of-Multi-Target-Therapeutics.aspx Smart multi-target drugs are reshaping modern therapeutics by addressing the complex, interconnected pathways that drive diseases like Alzheimer’s, cancer, and major depressive disorder. Advances in AI, molecular modeling, and network pharmacology are accelerating their development and improving therapeutic precision.

Shepherd’s Purse and Women’s Health: Abnormal Bleeding, Hormones, and More

https://www.news-medical.net/health/Shepherde28099s-Purse-and-Womene28099s-Health-Heavy-Menstruation-Hormones-and-More.aspx Shepherd’s Purse is a traditionally used Brassicaceae herb with emerging scientific support for its hemostatic, anti-inflammatory, and antioxidant properties. Modern analyses confirm the presence of bioactive flavonoids, glucosinolates, and uterotonic peptides that may aid in the treatment of bleeding disorders, inflammation, and dermatologic applications.

What Is Angelica Root? Benefits, Nutrition, and How It Supports Women’s Health

What Is Angelica Root? Benefits, Nutrition, and How It Supports Women’s Health https://www.news-medical.net/health/What-Is-Angelica-Root-Benefits-Nutrition-and-How-It-Supports-Womene28099s-Health.aspx Angelica root is a traditionally used medicinal herb with emerging scientific evidence supporting its anti-inflammatory, circulatory, neurological, and reproductive effects. Current research suggests promising benefits for women’s health, though most findings remain preclinical or based on multi-herb formulations.

Metformin fails to improve insulin resistance in type 1 diabetes

https://www.news-medical.net/news/20251126/Metformin-fails-to-improve-insulin-resistance-in-type-1-diabetes.aspx A 26-week trial reveals that metformin, long viewed as a promising add-on therapy, lowers insulin needs but leaves tissue-level insulin resistance unchanged.

Editorial The next decade in AMR: getting the basics right The Lancet Microbe +...

Nov 2025 Volume 6Number 11 https://www.thelancet.com/journals/lanmic/issue/vol6no11/PIIS2666-5247(25)X0011-2

Editorial p987 Diabetes support at work: an unmet need The Lancet Diabetes & Endocrinology +...

Dec 2025 Volume 13Number 12p987-1078, e15 https://www.thelancet.com/journals/landia/issue/vol13no12/PIIS2213-8587(25)X0012-7

Editorial p987 Celebrating decades of progress in Lewy bodies research The Lancet Neurology +...

Dec 2025 Volume 24Number 12p987-1078, e14 https://www.thelancet.com/journals/laneur/issue/vol24no12/PIIS1474-4422(25)X0012-0

Public trust: the vaccine against vaccine hesitancy The Lancet Respiratory Medicine ++... ++

Public trust: the vaccine against vaccine hesitancy The Lancet Respiratory Medicine https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(25)00406-0/fulltext?dgcid=raven_jbs_etoc_email Dec 2025 Volume 13Number 12p1041-1118, e59-e63 https://www.thelancet.com/journals/lanres/issue/vol13no12/PIIS2213-2600(25)X0012-6 Association of respiratory drive and effort with mortality and time to discharge in patients on mechanical ventilation in Canada: a longitudinal, prospective, registry-based cohort study https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(25)00297-8/abstract?dgcid=raven_jbs_etoc_feature_lanres Projecting the 30-year burden of obstructive sleep apnoea in the USA: a prospective modelling study https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(25)00243-7/abstract?dgcid=raven_jbs_etoc_feature_lanres

Innate immunity regulation of brain health: a webinar from The Lancet Group and Cell Press

https://www.bigmarker.com/lancet-webinars/innate-immunity-regulation-of-brain-health-a-webinar-from-the-lancet-group-and-cell-press?utm_bmcr_source=hubspot_email_ondemand_tlcp_neuroimmunology&_hsmi=391631910&_hsenc=p2ANqtz--EJHb4g0_6LLV-JV73Mw3H37x2nqfutWVlKAQ3e_vYZ8WDbvXb2_OpB55u5twBkxHsjsVG8VN2iVt5vY8wrJgMaYg9JQ&hsCtaAttrib=197536830291 In case you missed it, we are pleased to share with you The Lancet Group and Cell Press's joint webinar on innate immunity regulation of brain health, now available to watch on-demand. Access is free with registration and you can watch the webinar here. Co-chairs Elena Becker-Barroso, Editor-in-Chief at The Lancet Neurology, and Sam Rose, Scientific Editor at Neuron, are joined by a panel of experts to discuss the importance of innate immunity in the development of neurological diseases: David Hunt, Professor of Medicine, University of Edinburgh, UK Andrea Ablasser, Professor, École polytechnique fédérale de Lausanne (EPFL), Switzerland Manuel Friese, Professor of Neurology and Director of the Institute of Neuroimmunology and Multiple Sclerosis (INIMS), University Medical Center Hamburg-Eppendorf, Germany Our panellists review potential therapeutic targets to protect neurons from inflammation-induced neurodegeneration in multiple sclerosis, discuss common features of innate immunity across neurodegenerative diseases and the neuroimmune interactions that can propagate neurotoxicity, and examine the triggers of these mechanisms in neurons and glia. We hope you find this webinar to be informative and useful to your work, and invite you to explore the additional resources below.

Developing a first-in-class therapy for GRIN-NDD Radiprodil is in development as the first therapy designed to directly address the underlying biology of GRIN-related neurodevelopmental disorder.

https://www.drugdiscoverynews.com/developing-a-first-in-class-therapy-for-grin-ndd-16784?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz--gndxxi8gEUcc3gjy3M4BoKlGbUNEX1DDcLuiKrtYFj9-nAzYtAhtELMbLMO9PmA0CDwDS7mdAT-ftOhAXhwClkzaQBA&_hsmi=391788877&utm_content=391788877&utm_source=hs_email

Platform-based CRISPR therapies promise faster, safer treatments Cross-industry collaborations, coupled with technology innovations, could help bring CRISPR therapies to millions of patients with genetic diseases.

https://www.drugdiscoverynews.com/platform-based-crispr-therapies-promise-faster-safer-treatments-16823

Topical Drugs Toxic for Pets | Ocular Rosacea: What to Know +++++++++ +++ +...

Expert Perspectives on the Latest Clinical Trial Updates in HR-Positive, HER2-Negative Early Breast Cancer Authors: Stephen R. D. Johnston, MA, FRCP, PhD; Priya Rastogi, MD

https://www.medscape.org/viewarticle/1002908?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251125-OUS-HONC-1002908-cta

FDA Approves a New Treatment for Primary Immunoglobulin A Nephropathy

https://content.govdelivery.com/accounts/USFDA/bulletins/3fd270a FDA Approves a New Treatment for Primary Immunoglobulin A Nephropathy The U.S. Food and Drug Administration (FDA) granted accelerated approval to Voyxact (sibeprenlimab-szsi) injection to reduce proteinuria (protein in the urine) in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761434s000lbl.pdf?utm_medium=email&utm_source=govdelivery Disease or Condition IgAN is a serious kidney disease that occurs when an abnormal form of an antibody called immunoglobulin A (IgA) deposits in the kidneys, causing kidney inflammation and damage. This kidney damage can cause protein to leak into the urine (proteinuria) and progressive kidney function decline. The disease is often diagnosed in young adults and can progress to kidney failure. Data Supporting Voyxact The efficacy and safety of Voyxact were evaluated in a randomized, double-blind, placebo-controlled trial (NCT05248646) in adults with biopsy-confirmed IgAN. Half of the patients received Voyxact, and the other half received a placebo. The primary efficacy endpoint assessed the change from baseline in proteinuria (urine protein-to-creatinine ratio sampled from a 24-hour urine collection) after 9 months of treatment in the first 320 patients who had the opportunity to reach the Month 9 visit. At 9 months, patients in the Voyxact group had a 50% reduction in proteinuria as compared to a 2% increase in proteinuria in the placebo group. https://clinicaltrials.gov/study/NCT05248646?utm_medium=email&utm_source=govdelivery The recommended dosage for Voyxact is 400 mg injected subcutaneously (under the skin) once every four weeks. Safety Information Voyxact suppresses the immune system and may increase the risk of infections. Patients should be assessed for active infections before starting Voyxact and monitored for signs of infection during treatment. Voyxact may interfere with the immune response to vaccines and increase the risk of infection from live vaccines. Administration of live vaccines is not recommended within 30 days prior to starting Voyxact or during treatment with Voyxact. The most common side effects of Voyxact are infections (including upper respiratory tract infection) and injection site reactions, including injection site erythema (skin redness). Designations Voyxact was granted accelerated approval based on the reduction of proteinuria. It has not been established whether Voyxact slows kidney function decline over the long-term in patients with IgAN. As a condition of the accelerated approval, the ongoing VISIONARY trial must be completed to confirm that Voyxact slows kidney function decline over the long-term in patients with IgAN. Continued approval may be contingent upon verification of clinical benefit in this confirmatory trial. Voyxact also received priority review and Breakthrough Therapy designation for this indication.

Vitiligo: my changing sense of self

https://www.changingfaces.org.uk/ Vitiligo: my changing sense of self Joti Gata-Aura lives with the rare skin condition, vitiligo. Having learned over time how to feel comfortable in her own skin, Joti now advocates for people with vitiligo and other visible differences. As a woman of Indian heritage, she has had to learn to accept that her skin is always changing. Here she reflects on how her lived experiences have affected her own sense of self and cultural identity https://www.linkedin.com/pulse/vitiligo-my-changing-sense-self-rare-revolution-magazine-ltv9e/ Vitiligo: my changing sense of self https://rarerevolutionmagazine.com/vitiligo-my-changing-sense-of-self/ Written by Joe Rumney, RARE Revolution Interview with Joti Gata-Aura More than skin deep Joti Gata-Aura has navigated vitiligo since her diagnosis over 20 years ago. In that time, while also being a dedicated parent and teacher, she has embraced the role of educator and campaigner for people with visible differences, which she does through her personal advocacy and through her work with the charities Changing Faces and The Vitiligo Society. Vitiligo is a rare long-term skin condition characterised by the loss of pigment, resulting in white patches which appear anywhere on the body. This occurs when the cells responsible for producing melanin—the pigment that gives skin its colour—are destroyed or stop functioning.1 While now a confident advocate, Joti hasn’t always felt strong in her own skin. In the early stages of her vitiligo journey, aged just 21 years old, she struggled with increasing depression and anxiety as her skin started to change, particularly on her face. There were periods when she couldn’t even open the door to visitors who called at her house— feeling compelled to hide her skin from the outside world. She would often think of excuses to avoid contact with other people, “Those initial few years were really hard. I think people look at me now and forget the hard times I’ve gone through”, Joti explains. https://vitiligosociety.org/

martes, 25 de noviembre de 2025

The hidden reason lung cancer screening is not working We’re still blaming patients

https://www.statnews.com/2025/11/25/lung-cancer-screening-criteria-study/ By Lisa Carter-BawaNov. 25, 2025 Carter-Bawa is a behavioral scientist and director of the Cancer Prevention Precision Control Institute at the Hackensack Meridian Center for Discovery & Innovation.

Tech-enabled caregiving can help dementia patients stay at home — perhaps for too long Connected care in a digital world comes with promise and peril

https://www.statnews.com/2025/11/24/dementia-caregiving-technology-assistance/ By Jason KarlawishNov. 24, 2025 Karlawish is a professor of medicine, medical ethics, health policy, and neurology at the University of Pennsylvania’s Perelman School of Medicine and co-director of the Penn Memory Center.

A new chapter in cardiovascular disease: Landmark data signals breakthrough moment

https://www.statnews.com/sponsor/2025/11/19/a-new-chapter-in-cardiovascular-disease-landmark-data-signals-breakthrough-moment/

Novo Nordisk’s semaglutide fails to slow Alzheimer’s progression The company started the trials after retrospective data indicated the drug might have an impact on the disease

https://www.statnews.com/2025/11/24/novo-nordisk-semaglutide-wegovy-ozempic-alzheimers-trial-failure/ By Andrew Joseph and Elaine ChenNov. 24, 2025

J&J’s novel Alzheimer’s drug fails in key trial, dimming hopes for a hot target Results could cast shadow over other experimental therapies aimed at the protein tau

https://www.statnews.com/2025/11/24/alzheimers-disease-johnson-and-johnson-posdinemab/ By Damian Garde and Jason MastNov. 24, 2025

I have long Covid. Don’t call my chronic disease a ‘journey’ I would sooner call the experience a bad trip

https://www.statnews.com/2025/11/25/chronic-disease-journey-long-covid/?utm_campaign=daily_recap&utm_medium=email&_hsenc=p2ANqtz--BK4FZEc4fVx94VFbHQpbNcR5-knTJOx-OdcP3TOpsdH0uVxMnewhtjW8pLxqG8XLnjP3JY9ySf2i9hViUBebiHsPjtQ&_hsmi=391672888&utm_content=391672888&utm_source=hs_email By Peter SwensonNov. 25, 2025 Swenson is professor emeritus in the Yale University Department of Political Science.

Can variant interpretation at scale unlock faster answers for rare disease patients?

https://www.statnews.com/sponsor/2025/10/27/can-variant-interpretation-at-scale-unlock-faster-answers-for-rare-disease-patients/

Surprising scientists five years after the pandemic, coronavirus has not disappeared but continues to mutate and spread Siw Ellen Jakobsen | Science Norway | November 25, 2025

https://geneticliteracyproject.org/2025/11/25/surprising-scientists-five-years-after-the-pandemic-coronavirus-has-not-disappeared-but-continues-to-mutate-and-spread/

CRISPR opens the door toward treating common health threats like rising cholesterol Heidi Ledford | Nature | November 25, 2025

https://geneticliteracyproject.org/2025/11/25/crispr-opens-the-door-toward-treating-common-health-threats-like-rising-cholesterol/

An Expert Discussion of Key New Data in CLL and MCL: How May It Impact Future Practice? Authors: Paolo Ghia, MD, PhD; Kami Maddocks, MD

FDA approves durvalumab for resectable gastric or gastroesophageal junction adenocarcinoma

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-durvalumab-resectable-gastric-or-gastroesophageal-junction-adenocarcinoma?utm_medium=email&utm_source=govdelivery

Deficient ATP release in the brain drives depressive- and anxiety-like behaviors

https://www.news-medical.net/news/20251125/Deficient-ATP-release-in-the-brain-drives-depressive-and-anxiety-like-behaviors.aspx Deficient ATP release in the brain drives depressive- and anxiety-like behaviors In a new JNeurosci paper, Tian-Ming Gao and colleagues, from Southern Medical University, explored how adenosine triphosphate (ATP) signaling relates to depression and anxiety using male mice. ATP is a molecule that not only provides energy but also supports communication between neurons.

The ABC method for improving mental health

https://www.news-medical.net/news/20251125/The-ABC-method-for-improving-mental-health.aspx The ABC method for improving mental health These are troubling times, where there is much to worry about. Emergency preparedness has suddenly become a highly relevant topic, and many people are plagued by a sense of unease and even fear.

What is the future of the flu shot? New vaccines and antiviral injections that could offer significantly better and broader protection against the flu are now in clinical trials.

https://www.drugdiscoverynews.com/what-is-the-future-of-the-flu-shot-16821

Mold Exposure After Storms: How Big Is the Hidden Health Burden (Medscape AI)

https://www.medscape.com/ai-search?query=Mold%20Exposure%20After%20Storms:%20How%20Big%20Is%20the%20Hidden%20Health%20Burden&ecd=wnl_tp10_daily_251124_MSCPEDIT_etid7899675&uac=148436CN&impID=7899675

Join us for the NCSACW’s Upcoming Webinar: Substance Use Trends – The Effects on Child Safety and Family Risk Factors Wednesday, December 17, 2−3 p.m. ET

Join us for the NCSACW’s Upcoming Webinar: Substance Use Trends – The Effects on Child Safety and Family Risk Factors Wednesday, December 17, 2−3 p.m. ET https://cffutures.zoom.us/webinar/register/WN_jGPJ59jsSZ29KluWiX8GSg?utm_source=SAMHSA&utm_campaign=e218918fdf-EMAIL_CAMPAIGN_2025_11_21_08_17&utm_medium=email&utm_term=0_-e218918fdf-167840245#/registration Registration is free. Join the National Center on Substance Abuse and Child Welfare’s (NCSACW) for a webinar exploring how substance use trends affect child safety and family risk factors. National experts will share insights from the National Opioid Environmental Scan, discuss the rise of fentanyl and other substances, and offer strategies to improve outcomes for families. Learn how evolving substance use patterns (e.g., fentanyl, stimulants, cannabis) shape child safety and family well-being. This session highlights strategies to reduce stigma and improve parent engagement in services, assess safety and risk factors with families affected by substance use, and strengthen protective capacities in families. It’s designed for professionals across child welfare, substance use treatment, courts, and health care systems. Topics include: How do evolving substance use patterns affect children and families? How does stigma shape access to services and outcomes for families affected by substance use? What are some strategies to assess safety and risk while building protective capacities in families? Meet our presenters: Nancy K. Young, Ph.D., M.S.W, Executive Director of Children and Family Futures Andrea Sivanich, Ph.D., J.D., Deputy Program Director at the Center for Children and Family Futures (CCFF)

Experience Pills. Practical Insights for Early Diagnosis and Management of Biliary Tract Cancers (BTCs)

https://pillsbtc.gruposaned.com/index.php/prof-heather-dawson/?utm_source=saned&utm_medium=email&utm_campaign=saned_dawson Welcome back to the “Experience Pills: Practical Insights for the Early Diagnosis and Management of Biliary Tract Cancers (BTC)” program, a medical education initiative designed to equip primary care and oncology specialists with the essential tools for early detection and effective management of BTC, ultimately aiming to improve patient outcomes. The program includes six video training pills, each accompanied by a detailed monograph, that have been developed by a panel of international experts. The pills will be released progressively from October 2025 to January 2026. You can now access the third training pill. https://pillsbtc.gruposaned.com/index.php/prof-heather-dawson/?utm_source=saned&utm_medium=email&utm_campaign=saned_dawson

Making prostate cancer screening fit for purpose The Lancet Oncology ++ +...

Making prostate cancer screening fit for purpose The Lancet Oncology https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00672-2/fulltext?dgcid=raven_jbs_etoc_email The human crisis in cancer: a Lancet Oncology Commission https://www.thelancet.com/commissions-do/human-crisis-in-cancer?dgcid=raven_jbs_etoc_feature_lanonchumancrisis25 Dec 2025 Volume 26Number 12p1511-1684, e620-e706 https://www.thelancet.com/journals/lanonc/issue/vol26no12/PIIS1470-2045(25)X0012-7

Unraveling the mycobiome's role in cancer

https://www.news-medical.net/news/20251125/Unraveling-the-mycobiomes-role-in-cancer.aspx

CORRECTION: FDA Approves Reformulated Ranitidine

Correction: Yesterday, the U.S. Food and Drug Administration approved VKT Pharma's reformulated Ranitidine tablets in 150 mg and 300 mg strengths, marking the return of this important acid-reducing medication to the U.S. market after a five-year absence. FDA Approves Reformulated Ranitidine Today, the U.S. Food and Drug Administration approved VKT Pharma's reformulated Ranitidine tablets in 150 mg and 300 mg strengths, marking the return of this important acid-reducing medication to the U.S. market after a five-year absence. The approval follows extensive safety testing and manufacturing improvements that address previous concerns about N-nitrosodimethylamine (NDMA) impurity formation during the product’s shelf-life. Clinical Considerations: Healthcare providers and patients should be aware that the reformulated ranitidine maintains the same therapeutic effectiveness as previously approved products. Patients currently using alternative H2 blockers or proton pump inhibitors should consult their healthcare providers before switching medications. Approved products will include updated labeling with storage and handling instructions. Patients and healthcare providers should consider the new storage conditions for the safe and effective use of the product which include: Keep Ranitidine Tablets in the original container (bottle) and protect from moisture. After the first opening of the bottle, discard unused tablets after 3 months (90 days), or by the expiration date on the bottle, whichever is sooner. If more than one bottle is dispensed, open only one bottle at a time. Store additional bottles without opening until needed for dosing. At the time of dosing, remove one tablet from the bottle. Immediately close the bottle, secure the cap, and keep the bottle tightly closed. Keep the desiccant in the bottle. This approval is expected to increase patient access to this important medication for patients who rely on it for various health conditions. As always, patients should consult with their healthcare providers about the best treatment options for their individual needs.

Fluoride levels in U.S. drinking water linked to better teen cognition

https://www.news-medical.net/news/20251125/Fluoride-levels-in-US-drinking-water-linked-to-better-teen-cognition.aspx A landmark U.S. study tracking students from high school to age 60 reveals that recommended fluoride levels support stronger academic performance in adolescence but offer no measurable cognitive edge in later adulthood.

Addressing Challenges for Patients With HR+/HER2- EBC: Managing AEs and Optimizing Adherence Authors: Sarah Donahue, MPH, NP, AOCNP; Erika Hamilton, MD; Nadia Harbeck, MD, PhD

https://www.medscape.org/viewarticle/1002936?sso=true&uac=148436CN&src=mkmcmr_reeng_recap_mscpedu_activity Addressing Challenges for Patients With HR+/HER2- EBC: Managing AEs and Optimizing Adherence Below are some key learning points to help reinforce the impact of this activity. ☑ The Patient Journey • Understand the patient's treatment journey, including common challenges and adverse events (AEs) • Encourage proactive communication, so patients feel comfortable reporting concerns and AEs to their care team ☑ Managing Adverse Events • Review common AEs of abemaciclib and ribociclib • Educate the patient about what to expect when initiating adjuvant CDK4/6 therapy • Employ strategies to mitigate AEs, including the potential of a lower starting dose of abemaciclib and dose reduction ☑ Monitoring for Recurrence • Review the monitoring guidelines for CDK4/6 inhibitors • Assess your care models for monitoring patients on adjuvant CDK4/6 therapy ☑ Develop best practices for managing the growing number of patients on adjuvant CDK4/6 therapy • Train oncology coaches • Work with your intraprofessional and interprofessional team • Use patient self-reporting tools

ESMO ASIA 2025 INDUSTRY SATELLITE SYMPOSIUM Precision Oncology in HER2-Mutated NSCLC Strategies for Today and Tomorrow CME Suntec Singapore Convention & Exhibition Centre Sunday, 7 December 2025 | 12:30 - 14:00 SGT

ESMO ASIA 2025 INDUSTRY SATELLITE SYMPOSIUM Precision Oncology in HER2-Mutated NSCLC Strategies for Today and Tomorrow CME Suntec Singapore Convention & Exhibition Centre Sunday, 7 December 2025 | 12:30 - 14:00 SGT https://events.medscapelive.org/website/90731/?language=eng&utm_campaign=445508.01a%2F445510.01a_esmo+asiahemoncsolidtumor%5Bonco%5D_thlive_bayer_edu&utm_source=mrk&utm_medium=em&utm_content=int Join our distinguished panel of experts for a dynamic and engaging symposium that deep dives into the latest cutting-edge developments for HER2-mutated non-small cell lung cancer (NSCLC). Gain mastery of molecular testing and implementation of evidence-based strategies with HER2-directed therapies to personalize treatment and ease the burden of disease. IMPORTANT NOTICE: To attend this symposium, whether in person or virtually, you must first register directly with the ESMO ASIA CONGRESS 2025. Please visit the official congress website for full registration details and requirements.

Can AI take the guesswork out of CRISPR? New AI tools promise to speed up and simplify CRISPR experiments, but their real-world impact is still being tested.

https://www.drugdiscoverynews.com/?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-8DJebAdRM7XY_BkoVQ1v_Ceet9OkbL58EKgjwp3KbD3ptwyWEDcR8fyRx1s43K8ypTJM9Z7xVqPCNFk-OF1FvDPlREgQ&_hsmi=391406645&utm_content=391406645&utm_source=hs_email

Update to the Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection Content From: HIV.gov• Published: November 24, 2025 +... ++++++

https://www.hiv.gov/blog/update-to-the-guidelines-for-the-use-of-antiretroviral-agents-in-pediatric-hiv-infection?j=2837391&sfmc_sub=6992026&l=6498_HTML&u=70122903&mid=100006181&jb=0 When to Initiate Antiretroviral Treatment in Children With HIV Infection https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv/when-initiate-therapy-antiretroviral-naive-children Management of Children Receiving Antiretroviral Therapy https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv/overview-2?view=full Table 18. Examples of Changes in Antiretroviral Regimen Components for Children With Sustained Virologic Suppression https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv/modifying-antiretroviral-regimens-children-sustained-virologic-suppression#table18 Special Considerations for Antiretroviral Therapy Use in Adolescents With HIV https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv/specific-considerations-antiretroviral-therapy-use-adolescents-hiv?view=full Appendix A: Pediatric Antiretroviral Drug Information https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv/overview-0?view=full What's New in the Guidelines https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv/whats-new

Monitoring ESR1 ctDNA During First-Line Care of HR-Positive Advanced Breast Cancer: A New Approach Authors: François-Clément Bidard, MD, PhD; Nicola Fusco, MD, PhD

https://www.medscape.org/viewarticle/1002782?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251124-OUS-HONC-1002782-cta

Clinical Severity & Management The Most Aggressive Types of Pneumonia https://www.medscape.com/viewarticle/most-aggressive-types-pneumonia-2025a1000rkm?ecd=mkm_ret_251125_mscpmrk-OUS_InFocus_etid7893275&uac=148436CN&impID=7893275 Severe Community-Acquired Pneumonia https://www.medscape.com/viewarticle/quick-take-severe-community-acquired-pneumonia-2025a1000v9u?ecd=mkm_ret_251125_mscpmrk-OUS_InFocus_etid7893275&uac=148436CN&impID=7893275 Steroids May Lower Death Risk in CAP https://www.medscape.com/viewarticle/steroids-may-lower-death-risk-community-acquired-pneumonia-2025a1000ufb?ecd=mkm_ret_251125_mscpmrk-OUS_InFocus_etid7893275&uac=148436CN&impID=7893275 Aspiration Pneumonitis or Aspiration Pneumonia? https://www.medscape.com/viewarticle/quick-take-aspiration-pneumonitis-or-aspiration-pneumonia-2025a1000t97?ecd=mkm_ret_251125_mscpmrk-OUS_InFocus_etid7893275&uac=148436CN&impID=7893275 Epidemiology, Risk Factors & Prevention Winter Fears as Respiratory Admissions Climb https://www.medscape.com/viewarticle/winter-fears-respiratory-admissions-climb-2025a1000w2r?ecd=mkm_ret_251125_mscpmrk-OUS_InFocus_etid7893275&uac=148436CN&impID=7893275 Global Childhood Vaccination Stalls, 2030 Targets at Risk https://www.medscape.com/viewarticle/global-childhood-vaccination-stalls-2030-targets-risk-2025a1000iqx?ecd=mkm_ret_251125_mscpmrk-OUS_InFocus_etid7893275&uac=148436CN&impID=7893275 Biomass Cooking Pollution Not Linked to Pneumonia in Infants https://www.medscape.com/viewarticle/biomass-cooking-pollution-not-linked-pneumonia-infants-2025a1000w6k?ecd=mkm_ret_251125_mscpmrk-OUS_InFocus_etid7893275&uac=148436CN&impID=7893275

https://www.workcast.com/register?cpak=9670327140636502&utm_campaign=MAL_HUM&utm_medium=email&_hsenc=p2ANqtz-9sAdSF6lNaIBZfPrFtDhEiU_BjrSz6d6FxkLRGFBCnJPJ2M4I2a1TyujMCr3OnUzkw9dIW_WW6e75JGngFI8sAH0j5aQ&_hsmi=390845464&utm_content=390845464&utm_source=hs_email Enabling AAV Gene Therapy Development: From Discovery to Release Gene therapy development demands models that truly reflect human biology. Ncardia’s iPSC-derived platforms provide scalable, disease-relevant systems to evaluate efficacy, toxicity and potency aligned with clinical needs. We collaborate with innovators across multiple disease areas, integrating iPSC-based screening into the developments of AAV. By applying human biology early – and keeping the ultimate goal of patient-ready therapies in sight – we help identify the most promising candidate therapy, reduce risk, and accelerate progress.

Now Available: Highlights from the Current Issue +++

Advancing Potency Assay Development for Advanced Therapy Medicinal Products: A Comprehensive Approach and Regulatory Insights Alaa Abdellatif, Melissa Bou Jaoudeh, Alex Zwiers, and Gabrièle Breda https://www.liebertpub.com/doi/10.1089/hum.2024.249?utm_campaign=MAL_HUM&utm_medium=email&_hsenc=p2ANqtz-9gXPsv4rGkc2mOU4et9-o_m5kwwvRxiSEt2t1k1zsoiJ3s4VbEWkEBuO4pkq75ctR6G9ts1AxzKEyiMtcn8hAYbMmACA&_hsmi=390845464&utm_content=390845464&utm_source=hs_email The Lived Experience of Pediatric Gene Therapy Clinical Trial in Duchenne Muscular Dystrophy: Exploring Perceptions of Parents and Professionals Using Social Representation Method Shotaro Tachibana, Dominique Vincent-Genod, Pascal Rippert, Carole Vuillerot, and Silvana De Lucia https://www.liebertpub.com/doi/10.1177/10430342251359998?utm_campaign=MAL_HUM&utm_medium=email&_hsenc=p2ANqtz--niSjfFQjaMTocSBMIN3NawJANsMv9YqGzxdiSWSJDAZ59M_YzTzZhUez3TjzxzTZhRuXroVEcwB3A1WTVswVNDrRJgA&_hsmi=390845464&utm_content=390845464&utm_source=hs_email Long-Term Functional Correction of Pompe Disease and Increased α-Glucosidase Expression after Gene Therapy with Novel Combinations of Muscle-Targeted Transcriptional Cis-Regulatory Elements Quang Hong Pham, Venkata Anudeep Bheemsetty, Phuong Anh Nguyen, Ermira Samara-Kuko, Fangye Gao, Marinee K. Chuah, and Thierry VandenDriessche https://www.liebertpub.com/doi/10.1177/10430342251359989?utm_campaign=MAL_HUM&utm_medium=email&_hsenc=p2ANqtz--XFOpn1pT0Anb6oJ5fYZXmgL_x9FGavN2ioG0JNMtwKbhXdjHwy-OkxEooJNDfxWEEAwHPUEpNQl9zbjyRUiFJecFhig&_hsmi=390845464&utm_content=390845464&utm_source=hs_email

‘Perfect storm’: Doctors warn of alarming rise in adult-onset food allergies By Ashley J. DiMella Fox News Published November 23, 2025 4:02pm EST

‘Perfect storm’: Doctors warn of alarming rise in adult-onset food allergies Shellfish emerges as top allergen among adults as researchers investigate gut health connection Ashley J. DiMella By Ashley J. DiMella Fox News Published November 23, 2025 4:02pm EST https://www.foxnews.com/health/perfect-storm-doctors-warn-alarming-rise-adult-onset-food-allergies

New weight-loss shot shows major fat reduction, but experts urge caution By Melissa Rudy Fox News Published November 24, 2025 7:00am EST

New weight-loss shot shows major fat reduction, but experts urge caution Experimental drug could be combined with Ozempic and other GLP-1s, researchers say Melissa Rudy By Melissa Rudy Fox News Published November 24, 2025 7:00am EST https://www.foxnews.com/health/new-weight-loss-shot-shows-major-fat-reduction-trial-experts-urge-caution